Robert H. Shoemaker

24.3k total citations · 7 hit papers
189 papers, 20.4k citations indexed

About

Robert H. Shoemaker is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Robert H. Shoemaker has authored 189 papers receiving a total of 20.4k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Molecular Biology, 73 papers in Oncology and 39 papers in Cancer Research. Recurrent topics in Robert H. Shoemaker's work include Cancer therapeutics and mechanisms (17 papers), Cancer, Hypoxia, and Metabolism (16 papers) and Drug Transport and Resistance Mechanisms (15 papers). Robert H. Shoemaker is often cited by papers focused on Cancer therapeutics and mechanisms (17 papers), Cancer, Hypoxia, and Metabolism (16 papers) and Drug Transport and Resistance Mechanisms (15 papers). Robert H. Shoemaker collaborates with scholars based in United States, Germany and Italy. Robert H. Shoemaker's co-authors include Dominic A. Scudiero, Anne Monks, Michael R. Boyd, Kenneth D. Paull, Donald L. Fine, Michael C. Alley, Betty J. Abbott, Joseph G. Mayo, Philip Skehan and Maciej Czerwiński and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Robert H. Shoemaker

186 papers receiving 19.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines

1991 2.9k citations Anne Monks, Dominic A. Scudiero et al. profile →
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

1988 2.8k citations Dominic A. Scudiero, Anne Monks et al. profile →
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

1988 2.1k citations Dominic A. Scudiero, Robert H. Shoemaker et al. profile →
The NCI60 human tumour cell line anticancer drug screen

2006 2.0k citations Robert H. Shoemaker profile →
Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines

1990 859 citations Robert H. Shoemaker, Dominic A. Scudiero et al. profile →
Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm

1989 816 citations Robert H. Shoemaker, Anne Monks et al. profile →
New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity

1989 615 citations Robert H. Shoemaker et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert H. Shoemaker	10.8k	5.4k	4.2k	2.9k	1.9k	189	20.4k
Anne Monks	12.8k 1.2×	6.7k 1.3×	5.4k 1.3×	2.3k 0.8×	2.8k 1.4×	103	24.4k
Dominic A. Scudiero	16.3k 1.5×	6.9k 1.3×	6.2k 1.5×	3.3k 1.1×	2.9k 1.5×	95	28.1k
Ting‐Chao Chou	14.1k 1.3×	4.2k 0.8×	8.1k 1.9×	2.2k 0.8×	1.8k 0.9×	350	29.3k
Shaomeng Wang	20.8k 1.9×	5.4k 1.0×	7.0k 1.7×	1.9k 0.6×	1.4k 0.7×	459	29.3k
Hiroyuki Osada	11.8k 1.1×	4.5k 0.8×	2.7k 0.6×	2.0k 0.7×	4.0k 2.1×	663	19.5k
Christian Bailly	10.6k 1.0×	5.6k 1.0×	3.1k 0.7×	951 0.3×	1.5k 0.8×	520	17.4k
William A. Denny	12.4k 1.1×	8.4k 1.6×	4.3k 1.0×	2.6k 0.9×	827 0.4×	600	21.1k
Kurt W. Kohn	18.1k 1.7×	2.8k 0.5×	7.8k 1.9×	4.2k 1.4×	1.1k 0.5×	272	24.0k
TOMIO TAKEUCHI	9.4k 0.9×	5.1k 0.9×	3.2k 0.8×	1.3k 0.4×	4.3k 2.2×	621	16.6k
Michael R. Boyd	12.6k 1.2×	9.5k 1.8×	2.9k 0.7×	2.3k 0.8×	4.3k 2.2×	389	28.6k

Countries citing papers authored by Robert H. Shoemaker

Since Specialization

Citations

This map shows the geographic impact of Robert H. Shoemaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Shoemaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Shoemaker more than expected).

Fields of papers citing papers by Robert H. Shoemaker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Shoemaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Shoemaker. The network helps show where Robert H. Shoemaker may publish in the future.

Co-authorship network of co-authors of Robert H. Shoemaker

This figure shows the co-authorship network connecting the top 25 collaborators of Robert H. Shoemaker. A scholar is included among the top collaborators of Robert H. Shoemaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert H. Shoemaker. Robert H. Shoemaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Janice, et al.. (2023). Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis—Inducing Genes S100A4 and MACC1. International Journal of Molecular Sciences. 24(2). 1179–1179. 10 indexed citations

Watts, Norman R., Elif Eren, Ira Palmer, et al.. (2023). The ribosome-inactivating proteins MAP30 and Momordin inhibit SARS-CoV-2. PLoS ONE. 18(6). e0286370–e0286370. 3 indexed citations

Mohammed, Altaf, Roderick H. Dashwood, Sally E. Dickinson, et al.. (2021). Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. Journal of Cancer Prevention. 26(4). 309–317. 1 indexed citations

Dahlmann, Mathias, Anne Monks, Erik Harris, et al.. (2021). Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers. 14(1). 37–37. 9 indexed citations

Datta, Arindam, Kajal Biswas, Joshua A. Sommers, et al.. (2021). WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells. Nature Communications. 12(1). 6561–6561. 31 indexed citations

Valencia, Sarah, Alexander Marin, Chelsea Sanders, et al.. (2021). Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP. Human Vaccines & Immunotherapeutics. 17(8). 2748–2761. 14 indexed citations

Zhang, Qi, Jing Pan, Donghai Xiong, et al.. (2021). Pulmonary Aerosol Delivery of Let‐7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment. Advanced Science. 8(17). e2100629–e2100629. 28 indexed citations

Harberts, Erin, Sarah Valencia, Chelsea Sanders, et al.. (2020). Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists. Vaccine. 39(2). 292–302. 20 indexed citations

Mohammed, Altaf, Mark Steven Miller, Ronald A. Lubet, et al.. (2019). Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. Cancer Prevention Research. 13(3). 273–282. 8 indexed citations

10.

Pan, Jing, Qi Zhang, Katie Palen, et al.. (2019). Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine. 49. 72–81. 49 indexed citations

11.

Lubet, Ronald A., Vernon E. Steele, Robert H. Shoemaker, & Clinton J. Grubbs. (2018). Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression. Cancer Prevention Research. 11(10). 595–606. 4 indexed citations

12.

Aggarwal, Monika, Taraswi Banerjee, Joshua A. Sommers, et al.. (2013). Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway. Cancer Research. 73(17). 5497–5507. 65 indexed citations

13.

Chen, David Y., Brian A. Van Tine, Adam C. Searleman, et al.. (2011). A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth. Cancer Research. 72(3). 736–746. 35 indexed citations

14.

Calvani, Maura, Daniela Trisciuoglio, Cristina Bergamaschi, Robert H. Shoemaker, & Giovanni Melillo. (2008). Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells. Cancer Research. 68(1). 285–291. 63 indexed citations

15.

Cardellina, John H., Andrew G. Stephen, Annamaria Rapisarda, et al.. (2007). Cell Type–Specific, Topoisomerase II–Dependent Inhibition of Hypoxia-Inducible Factor-1α Protein Accumulation by NSC 644221. Clinical Cancer Research. 13(3). 1010–1018. 45 indexed citations

16.

Gills, Joell J., Jaclyn LoPiccolo, Junji Tsurutani, et al.. (2007). Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo. Clinical Cancer Research. 13(17). 5183–5194. 264 indexed citations

17.

Jensen, Lars H., Peter Bjødstrup Jensen, Robert H. Shoemaker, & Maxwell Sehested. (2006). SAR analysis of substituted purines as topoisomerase II inhibitors identifies ATPase inhibitors with nanomolar activity.. Cancer Research. 66. 1301–1301. 2 indexed citations

18.

Krosky, Paula M., Susan Kenney, David T. Vistica, Dominic A. Scudiero, & Robert H. Shoemaker. (2006). NSC13778 disrupts interactions between transcription factors TFE3, ASPL-TFE3 type 1, and ASPL-TFE3 type 2 and cognate DNA. Cancer Research. 66. 1086–1086. 2 indexed citations

19.

Kong, Dehe, Eun‐Jung Park, Andrew G. Stephen, et al.. (2005). Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity. Cancer Research. 65(19). 9047–9055. 431 indexed citations

20.

Laurençot, Carolyn M., George L. Scheffer, Rik J. Scheper, & Robert H. Shoemaker. (1997). Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. International Journal of Cancer. 72(6). 1021–1026. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact